CNCE News and Press, Concert Pharmaceuticals Inc. From 06/02/22

Concert Pharmaceuticals (NASDAQ:CNCE) priced its underwritten public offering of 10M shares at a public offering price of $4.75/share Gross proceeds are expected to be ~$47.5M. Underwriters granted 30-day option to purchase up to an additional 1.5M shares. Offering is expected to cl...

Gainers: Tonix Pharmaceuticals Holding (TNXP) +60%. Helius Medical Technologies (HSDT) +40%. View (VIEW) +42%. Spark Networks (LOV) +32%. Regencell Bioscience Holdings (RGC) +21%. 180 Life Sciences (ATNF) +20%. Evelo Biosciences (EVLO) +17%. NeuroOne Medical Technologies Corporation (NMTC) +1...

Gainers: Helius Medical Technologies (HSDT) +57%. Tonix Pharmaceuticals  TNXP +49%. NeuroOne Medical Technologies (NMTC) +16%. Oncternal Therapeutics (ONCT) +16%. Butterfly Network (BFLY) +15%. Losers: Enochian Biosciences ENOB -37%. Icosavax ...

Concert Pharmaceuticals (NASDAQ:CNCE), a clinical-stage biotech focused on autoimmune diseases, has lost ~15% in the pre-market Wednesday after the company announced an underwritten public offering of 10M shares of its common stock. A decision to grant a 30-day option for underwrite...

Gainers: Elevation Oncology (ELEV) +9%. INMODE  (INMD) +6%. Inspirato Incorporated (ISPO) +5%. Ranger Oil Corporation (ROCC) +5%. Anavex Life Sciences  (AVXL) +5%. Losers: Concert Pharmaceuticals (CNCE) -17%. Chindata Group Holdings Limited (CD) -11%. Conn's (CONN) -7%. Am...

Gainers: Avadel Pharmaceuticals (AVDL) +123%. SIGA Technologies (SIGA) +40%. Concert Pharmaceuticals (CNCE) +30%. Farfetch (FTCH) +25%. Allarity Therapeutics (ALLR) +25%. Merus N.V. (MRUS) +23%. Tenon Medical (TNON) +22%. Arcturus Therapeutics Holdings (ARCT) +19%. Red Rob...

Gainers: Apyx Medical (APYX) +39%. Enochian Biosciences (ENOB) +17%. Concert Pharmaceuticals (CNCE) +14%. GeoVax Labs (GOVX) +14%. Liquidia (LQDA) +13%. Losers: NRx Pharmaceuticals (NRXP) -57%. Avadel Pharmaceuticals (AVDL) -44%. Nurix Therape...

Dollar Tree DLTR +17% on Q1 results. Build-A-Bear Workshop BBW +17% on Q1 results. Destination XL DXLG +15% on Q1 results. Joby Aviation JOBY +15% after receipt of FAA Part 135 Air Carrier Certificate. Macy's M +14% on Q1 results. Dollar Gener...

Concert Pharmaceuticals (NASDAQ:CNCE) said a phase 3 trial of its oral drug CTP-543 met the main goal of scalp hair regrowth at both doses in patients with moderate to severe alopecia areata, an autoimmune disorder causing scalp hair loss. The late-stage study, called THRIVE-AA1, included 706...

THRIVE-AA1 Study Meets Primary Endpoint for Scalp Hair Regrowth and Key Secondary Endpoints at Both Doses Statistically Significant Hair Regrowth Observed as Early as Eight Weeks CTP-543 Has Potential to be Best-in-Class for the Treatment of Alopecia Areata Top...